Month: November 2022

Coordination polymers constructed by diverse metal centers and the rigid ligand 3,5-di(1H-imidazol-1-yl)pyridine. Synthesis, structure and properties was written by Luo, Li;Zhao, Yue;Lu, Yi;Okamura, Taka-aki;Sun, Wei-Yin. And the article was included in Polyhedron in 2012.COA of Formula: C11H9N5 The following contents are mentioned in the article:

Six new coordination polymers, [Cu(L)₂(H₂O)₂](NO₃)₂ (I), [Cu(L)₂](ClO₄)₂ (II), [Cd(L)₂(H₂O)₂](ClO₄)₂ (III), [Cd(L)(OAc)₂(H₂O)] (IV), [Cu₃(L)₄(H₂O)₂(SO₄)](SO₄)₂.30H₂O (V), and [Ni(L)(H₂O)₃(SO₄)] (VI) [L = 3,5-di(1H-imidazol-1-yl)pyridine, OAc^– = MeCOO^–], were prepared and characterized by x-ray diffraction, IR, elemental and thermogravimetric analyses. Complexes I, IV, and VI have different 1D chain structures, while II and III are 2D networks. The chains and layers are further linked together by H-bonds to generate 3D frameworks. Complex V is a (3,4,4)-connected 3D framework with a Point (Schlaefli) symbol of (4.8²)₄(4.8³.10²)₂(4².8².10²). The influences of the coordination modes of the ligand L, metal center as well as the counteranion on the structures of the complexes are discussed. Furthermore, the reversible anion exchange property of III and the photoluminescence properties of III and IV were investigated. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6COA of Formula: C11H9N5).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.COA of Formula: C11H9N5

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Optimization and kinetic study of biodiesel production through esterification of oleic acid applying ionic liquids as catalysts was written by Roman, Fernanda F.;Ribeiro, Antonio E.;Queiroz, Ana;Lenzi, Giane G.;Chaves, Eduardo S.;Brito, Paulo. And the article was included in Fuel in 2019.Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate The following contents are mentioned in the article:

In this study, 1-methylimidazolium hydrogen sulfate, [HMIM]HSO₄, ionic liquid, was successfully applied as a catalyst in the biodiesel production through the esterification reaction of oleic acid with methanol. A response surface methodol. (RSM) known as Box-Behnken Design (BBD) was applied to optimize the main exptl. reaction conditions, using a set of 27 experiments This optimization was based on the maximization of both the conversion of oleic acid and the Fatty Acid Me Esters (FAME) content of the obtained biodiesel samples. It was concluded that the two most relevant parameters for both the conversion and the FAME content were the molar ratio between oleic acid and methanol and the catalyst dosage. Accordingly to the model, the optimum condition for the maximum conversion was determined as being 8 h, 110 ± 2 °C, 15:1 M ratio methanol/oleic acid and a catalyst dosage of 15 wt%, resulting in a 95% conversion and for the maximum FAME content were 8 h, 110 ± 2 °C, 14:1 M ratio and a catalyst dosage of 14 wt%, leading to a FAME content of 90%. The kinetics of the esterification reaction was also evaluated, and the exptl. results were well described using a third-order reaction model. The kinetic parameters were exptl. determined, and the value of the activation energy was 6.8 kJ/mol and the pre-exponential factor was 0.0765 L².mol^-2.min^-1 confirming that the ionic liquid, [HMIM]HSO₄, is a good alternative for replacing traditional catalysts for biodiesel production through esterification reaction. This study involved multiple reactions and reactants, such as 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate).

1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate (cas: 478935-29-4) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Safety of 1-Hexyl-3-methyl-1H-imidazol-3-ium hydrogensulfate

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study was written by Rule, Simon;Barreto, Wolney Gois;Briones, Javier;Carella, Angelo M.;Casasnovas, Olivier;Pocock, Chris;Wendtner, Clemens-Martin;Zaja, Francesco;Robson, Susan;MacGregor, Lachlan;Tschopp, Roger R.;Nick, Sonja;Dreyling, Martin. And the article was included in Haematologica in 2022.Related Products of 16506-27-7 The following contents are mentioned in the article:

Rituximab plus chemotherapy induction followed by rituximab maintenance for up to 2 years confers a long-term benefit in terms of progression-free survival in patients with indolent non-Hodgkin lymphoma. It is not known whether further prolonged maintenance with rituximab provides addnl. benefit. The phase III MabCute study enrolled 692 patients with relapsed or refractory indolent non-Hodgkin lymphoma. Patients who responded to induction with rituximab plus chemotherapy and were still responding after up to 2 years’ initial maintenance with s.c. rituximab were randomized to extended maintenance with s.c. rituximab (n=138) or observation only (n=138). The primary endpoint of investigator-assessed progression-free survival in the randomized population was un-addressed by the end of study because of an insufficient number of events (129 events were needed for 80% power at 5% significance if approx. 330 patients were randomized). In total, there were 46 progression-free survival events, 19 and 27 in the rituximab and observation arms, resp. (P=0.410 by stratified log-rank test; hazard ratio 0.76 [95% confidence interval: 0.37-1.53]). The median progression-free survival was not reached in either randomized arm. There were no new safety signals; however, adverse events were seen slightly more frequently with rituximab than with observation during extended maintenance. Maintenance for up to 2 years with rituximab after response to initial induction therefore remains the standard of care in patients with relapsed or refractory indolent non-Hodgkin lymphoma. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Mn(II)/Co(II)-based metal-organic frameworks assembled by 5,5′-(1,4-xylylenediamino) diisophthalic acid and various nitrogen-containing ligands for photocatalytic and magnetic properties was written by Xu, Cungang;Luo, Rong;Zhang, Dongmei;Zhang, Xia;Zong, Ziao;Fan, Chuanbin;Zhu, Bin;Fan, Yuhua. And the article was included in Journal of Solid State Chemistry in 2021.Application In Synthesis of 3,5-Di(1H-imidazol-1-yl)pyridine The following contents are mentioned in the article:

Three novel Mn(II)/Co(II)-based 3D metal-organic frameworks (MOFs), namely {[Mn₂(L)(tib)(H₂O)]·3DMA·4H₂O}_n (1), {[Co₂(L)(bipd)₂]·3H₂O}_n (2) and {[Co(L)_0.5(bimb)]·3H₂O·0.5O₂}_n (3) (H₄L = 5,5′-(1,4-xylylenediamino)diisophthalic acid, tib = 1,3,5-tris(1-imidazolyl)benzene, bipd = 3,5-bis(1-imidazoly)pyridine, and bimb = 1,4-bis(lmidazol)-butane), have been successfully synthesized using the mixed-ligand as functionalized organic linker. The structural characterization revealed that both MOFs 1 and 2 exhibited an unprecedented 4-nodal 3D framework that enriching crystal engineering, while MOF 3 featured a 2-nodal three-interpenetrating bbf topol. framework with a Schlafli symbol of (6⁴·8²)(6⁶)₂. The title MOFs have been exploited as photocatalysts for degradation of methylene blue (MB), methyl violet (MV) and malachite green (MG). The photocatalytic results demonstrated that MOFs 2 and 3 exhibited efficient photocatalytic abilities to degrade the three aromatic dyes under UV irradiation The possible catalytic mechanism was also explored and discussed in detail. Moreover, the variable-temperature magnetic analyses indicated that MOFs 1–3 exhibited weak antiferromagnetic behavior between Mn(II)/Co(II) ions. This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6Application In Synthesis of 3,5-Di(1H-imidazol-1-yl)pyridine).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Application In Synthesis of 3,5-Di(1H-imidazol-1-yl)pyridine

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Impact of proton pump inhibitors on cytochrome P450 activity assessed by ¹³C-aminopyrine breath test in patients with cirrhosis was written by Rocco, Alba;Compare, Debora;Sgamato, Costantino;Coccoli, Pietro;Chiodini, Paolo;Nardone, Gerardo. And the article was included in Alimentary Pharmacology and Therapeutics in 2021.Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Summary : Background : Chronic use of proton pump inhibitors (PPIs) in patients with impaired liver function may worsen cytochrome P 450 (CYP450) activity, predisposing them to clin. relevant drug-drug interactions. The 13C-aminopyrine breath test (13C-ABT) is a non-invasive tool to study CYP450-dependent liver function. Aims : To assess 13C-ABT modifications with different PPIs in patients with cirrhosis. Methods : Sixty consecutive patients with HCV-related cirrhosis and indication to start PPI therapy were randomised to receive omeprazole 20 mg/day, esomeprazole 20 mg/day, lansoprazole 15 mg/day, pantoprazole 40 mg/day or rabeprazole 20 mg/day. 13C-ABT was performed at baseline and on the 15th day of PPI therapy. Results : At baseline, mean values of max 13C% dose/h and 13C% cum dose at 120 min did not differ significantly among groups. On the 15th day of therapy, max 13C% dose/h and 13C% cum dose at 120 min did not significantly differ with respect to baseline for pantoprazole (P = 0.184 and P = 0.309, resp.) or rabeprazole (P = 0.536 and P = 0.286, resp.), but were significantly decreased on omeprazole (P = 0.013 and P = 0.015, resp.), esomeprazole (P = 0.009 and P = 0.001, resp.), and lansoprazole (P = 0.033 and P = 0.035, resp.). Conclusions : In patients with cirrhosis, omeprazole, esomeprazole and lansoprazole inhibit microsomal activity while pantoprazole and rabeprazole do not have a significant impact. Should our data be confirmed in larger cohort studies, pantoprazole and rabeprazole could be safely recommended for patients with cirrhosis. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Effect of a rabeprazole half-dose twice daily on acid inhibition in patients with different CYP2C19 alleles was written by Murata, Masaki;Sugimoto, Mitsushige. And the article was included in European Journal of Clinical Pharmacology in 2020.Product Details of 117976-90-6 The following contents are mentioned in the article:

Abstract: Purpose: Fractional doses of proton pump inhibitors (PPIs) more often than once daily (qd) inhibit 24-h acid secretion more effectively than an increase in the standard single daily dose. Although rabeprazole 5 mg qd is covered for prevention of aspirin-induced gastric injury under the Japanese insurance system, it is unclear whether rabeprazole 5 mg twice daily (bid) would more effectively inhibit acid secretion. We compared acid inhibition between rabeprazole 10 mg qd and 5 mg bid in healthy volunteers with different alleles of CYP2C19. Methods: Twelve Helicobacter pylori-neg. healthy volunteers (CYP2C19 genotypes: extensive metabolizer (EM) (n = 6) and poor metabolizer (PM) (n = 6)) received three kinds of regimen for 7 days under a randomized crossover design: rabeprazole 5 mg qd (5 mg QD), 10 mg qd (10 mg QD), and 5 mg bid (5 mg BID). A 24-h pH monitoring was conducted before the trial and on day 7 of each regimen. Results: No significant differences in median pH values (4.0 (1.9-5.9)) and (4.4 (2.1-6.5)) or percent time of pH ≥ 4 (50.7% (11.9-86.8%) and 56.8% (19.3-83.9%)) were seen between the 10 mg QD and 5 mg BID regimens. Median pHs and percent time of pH ≥ 4 in CYP2C19 PMs were significantly higher than those in EMs. With 5 mg BID, there was no significant difference in percent-time with pH ≥ 4 between daytime and nighttime, but the 10 mg QD showed a significant difference. Conclusion: Rabeprazole 5 mg bid provided no therapeutic advantage for acid inhibition compared with rabeprazole 10 mg qd, regardless of CYP2C19 genotype status. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Product Details of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Product Details of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis was written by Oshima, Tadayuki;Igarashi, Ataru;Nakano, Hiroya;Deguchi, Hisato;Fujimori, Ikuo;Fernandez, Jovelle. And the article was included in Journal of Clinical Gastroenterology in 2022.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

This systematic review and network meta-anal. aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis. Limited available data directly compare the efficacy of vonoprazan, a first-in-class potassium-competitive acid blocker, with PPIs in erosive esophagitis. We conducted a systematic literature review (in MEDLINE and CENTRAL) and subsequent network meta-anal. according to Cochrane and PRISMA guidelines. Double-blind, randomized controlled trials in adults with erosive esophagitis treated with vonoprazan or a PPI were included in the anal. Primary outcomes were heartburn symptom resolution rate on Day 1 and Day 7. The study was performed with all available data, using a random effects model within a Bayesian framework. Overall, 10 randomized controlled trials were included in the network meta-anal. For heartburn resolution rate on Day 1 (9 of 10 trials), vonoprazan 20 mg once daily (QD) was superior to placebo (median odds ratio=16.75, 95% credible interval: 2.16-207.80). Point estimates numerically favored vonoprazan 20 mg QD over other comparators. For heartburn resolution rate on Day 7 (10 of 10 trials), vonoprazan 20 mg QD was superior to placebo and other comparators except rabeprazole 20 mg QD. Point estimates numerically favored vonoprazan 20 mg QD over rabeprazole 20 mg QD. In this study, vonoprazan 20 mg QD was equally effective in heartburn resolution on Day 1, and equally or more effective on Day 7 vs. PPIs in adults with erosive esophagitis. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Suppression of vacuolar-type ATPase and induction of endoplasmic reticulum stress by proton pump inhibitors was written by Lee, Wei-Ping. And the article was included in Journal of the Chinese Medical Association in 2022.Application of 117976-90-6 The following contents are mentioned in the article:

Proton pump inhibitors (PPIs), such as esomeprazole, pantoprazole, dexlansoprazole, and rabeprazole, are one of the most commonly prescribed medications. Several studies have linked the long-term use of PPIs to a potentially increased risk of gastric cancer. Therefore, this study aimed to determine the underlying mechanism of PPI-mediated gastric cancer. Lysosomes were isolated using immunoprecipitation The inhibition of vacuolar-type ATPase (V-ATPase) by PPIs was assayed using a PiColorLock Gold Phosphate Detection System. PPI-induced lysosomal stress was analyzed using transcription factor EB (TFEB) nuclear translocation. PPI-induced endoplasmic reticulum (ER) stress was analyzed using the expression of protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). Finally, reactive oxygen species (ROS) removal was determined using the activity of superoxide dismutase (SOD). PPIs caused a 70% inhibition of V-ATPase activity at 20 μM, leading to lysosomal stress through TFEB nuclear translocation; ER stress by inducing the expression of PERK, IRE1, and ATF6; and enhanced SOD activity for ROS removal. The long-term use of PPIs inhibits lysosomal V-ATPase, leading to ER stress and ROS accumulation, which may result in an increased risk of gastric cancer. Because lysosomes and the ER are common organelles in cells, physicians prescribing PPIs for gastroesophageal reflux and peptic ulcer diseases should pay more attention to the general effects of these agents on the human body. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Application of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Identification of novel and potential PPARγ stimulators as repurposed drugs for MCAO associated brain degeneration was written by Usman, Halima;Tan, Zhen;Gul, Mehreen;Rashid, Sajid;Ali, Tahir;Shah, Fawad Ali;Li, Shupeng;Li, Jing Bo. And the article was included in Toxicology and Applied Pharmacology in 2022.Related Products of 117976-90-6 The following contents are mentioned in the article:

Peroxisome proliferator-activated receptor-gamma (PPARγ) has been shown to have therapeutic promise in the treatment of ischemic stroke and is supported by several studies. To identify possible PPARγ activators, the current study used an in silico technique in conjunction with mol. simulations and in vivo validation. FDA-approved drugs were evaluated using mol. docking to determine their affinity for PPARγ. The findings of mol. simulations support the repurposing of rabeprazole and ethambutol for the treatment of ischemic stroke. Adult Sprague Dawley rats were subjected to transient middle cerebral artery occlusion (t-MCAO). Five groups were made as a sham-operated, t-MCAO group, rabeprazole +t-MCAO, ethambutol +t-MCAO, and pioglitazone +t-MCAO. The neuroprotective effects of these drugs were evaluated using the neurol. deficit score and the infarct area. The inflammatory mediators and signaling transduction proteins were quantified using Western blotting, ELISA, and immunohistochem. The repurposed drugs mitigated cerebral ischemic injury by PPARγ mediated downregulation of nods like receptor protein 3 inflammasomes (NLRP3), tumor necrosis factor-alpha (TNF-α), cyclooxygenase 2 (COX-2), nuclear factor kappa-light-chain-enhancer of activated B cells (p-NF-kB), and c-Jun N-terminal kinase (p-JNK). Our data demonstrated that rabeprazole and ethambutol have neuroprotective potential via modulating the cytoprotective stress response, increasing cellular survival, and balancing homeostatic processes, and so may be suitable for future research in stroke therapy. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Related Products of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Related Products of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Time to onset of bendamustine-associated skin damage using the spontaneous reporting system was written by Kashiwagi, Misui;Shimizu, Tadashi;Kawai, Rika;Kawashiri, Takehiro;Uesawa, Yoshihiro;Uchida, Mayako. And the article was included in Anticancer Research in 2022.Product Details of 16506-27-7 The following contents are mentioned in the article:

Bendamustine-associated skin damage occurs frequently in Japan and can have a profound impact on health-related quality of life. To our knowledge, there are no reports on the timing of skin damage caused by bendamustine. This study assessed trends in and the time to onset of skin damage caused by bendamustine using the Japanese Adverse Drug Reaction Reporting Database (JADER). Data related to skin damage with more than five reported cases from Apr. 2004 to March 2021 were extracted from JADER, and the relative risk of adverse events was estimated using the reporting odds ratio and 95% confidence interval. The data were analyzed for time to onset of skin damage. JADER included a total of 2,450 reports of adverse drug reactions from bendamustine. Of these, 170 skin ailments of 10 types were reported to be associated with bendamustine. Significant associations for skin damage were found for rash, herpes zoster, and infusion-related reactions. The reporting odds ratios (with 95% confidence interval) for rash, herpes zoster, and infusion-related reaction were 1.63 (1.19-2.21), 3.25 (2.20-4.78), and 7.25 (4.84-10.85), resp. The median onset (interquartile range) of rash, herpes zoster, and infusion-related reactions caused by bendamustine were 13 (10-28), 60 (28-107), and 6 (1-28) days, resp. A comprehensive study using a pharmacovigilance approach enabled us to identify that a rash or infusion-related reaction may be expected within 2 wk of treatment with bendamustine and that the onset of herpes zoster occurs at a median of 2 mo after treatment with bendamustine. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Product Details of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Product Details of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem